What conditions does Margituximab/Meganre treat?

Margetuximab (Margetuximab), as a targeted drug that has attracted much attention in the field of overseas breast cancer treatment in recent years, is a new type of HER2-targeting monoclonal antibody optimized through antibody engineering. Its development concept is not to completely replace traditional HER2-targeted regimens, but to provide a back-line option with immune-enhancing capabilities when these regimens have been used for many years and patients have a tendency to tolerate them or their effectiveness declines. For doctors and patients, understanding its "indications" is not only to understand the scope of drug coverage, but also an important basis for judging treatment paths.

The approval information shows that margituximab is suitable for use in combination with chemotherapy to treat metastatic disease Adult patients with HER2-positive breast cancer, provided that the patient has received at least two anti-HER2 treatment regimens, at least one of which is for the metastatic stage. This shows that the positioning of margetuximab is very clear. It belongs to the category of "late-line treatment" and is designed for patients who still have disease progression after multiple rounds of targeted therapy. After long-term use of traditional HER2 antibodies or small molecule drugs in such patients, the immune evasion ability of tumor cells often increases, the collaboration efficiency between immune cells and antibodies in the body gradually decreases, and the effectiveness of traditional antibodies also weakens over time. Therefore, a drug that is more capable of stimulating immune effects is needed to intervene.

The core innovation of margetuximab lies in “Fc fragment engineering”. Simply put, its structure is optimized to more easily bind to key cells in the immune system, such as NK cells, thereby enhancing antibody-dependent cytotoxic responses. This mechanism allows the immune system to be more efficient in recognizing HER2-positive tumors, and also allows patients to potentially benefit from immune enhancement after long-term treatment.

Reference materials:https://www.margenza.com/